Afficher la notice abrégée

GLP-1 Receptor Agonists and the Risk of Thyroid Cancer

dc.rights.licenseopenen_US
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBEZIN, Julien
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorGOUVERNEUR, Amandine
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorPENICHON, Marine
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorMATHIEU, Clement
dc.contributor.authorGARREL, Renaud
dc.contributor.authorHILLAIRE-BUYS, Dominique
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorPARIENTE, Antoine
IDREF: 13395711X
dc.contributor.authorFAILLIE, Jean-Luc
dc.date.accessioned2022-12-15T09:58:00Z
dc.date.available2022-12-15T09:58:00Z
dc.date.issued2022-11-10
dc.identifier.issn1935-5548 (Electronic) 0149-5992 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/171528
dc.description.abstractEnOBJECTIVE: To determine whether use of glucagon-like peptide 1 (GLP-1) receptor agonists (RA) is associated with increased risk of thyroid cancer. RESEARCH DESIGN AND METHODS: A nested case-control analysis was performed with use of the French national health care insurance system (SNDS) database. Individuals with type 2 diabetes treated with second-line antidiabetes drugs between 2006 and 2018 were included in the cohort. All thyroid cancers were identified through hospital discharge diagnoses and medical procedures between 2014 and 2018. Exposure to GLP-1 RA was measured within the 6 years preceding a 6-month lag-time period and considered as current use and cumulative duration of use based on defined daily dose (≤1, 1 to 3, >3 years). Case subjects were matched with up to 20 control subjects on age, sex, and length of diabetes with the risk-set sampling procedure. Risk of thyroid cancer related to use of GLP-1 RA was estimated with a conditional logistic regression with adjustment for goiter, hypothyroidism, hyperthyroidism, other antidiabetes drugs, and social deprivation index. RESULTS: A total of 2,562 case subjects with thyroid cancers were included in the study and matched with 45,184 control subjects. Use of GLP-1 RA for 1-3 years was associated with increased risk of all thyroid cancer (adjusted hazard ratio [HR] 1.58, 95% CI 1.27-1.95) and medullary thyroid cancer (adjusted HR 1.78, 95% CI 1.04-3.05). CONCLUSIONS: In the current study we found increased risk of all thyroid cancer and medullary thyroid cancer with use of GLP-1 RA, in particular after 1-3 years of treatment. ARTICLE HIGHLIGHTS: Preclinical studies suggest that GLP-1 receptor agonists have specific effects on the thyroid gland, potentially involving the development of thyroid cancer. Studies on this subject produced conflicting results, potentially due to a lack of statistical power. The results of this nationwide population-based study suggest that use of GLP-1 receptor agonists is associated with increased risk of thyroid cancer. The increased risk was higher in the case of 1-3 years of GLP-1 receptor agonist use. Clinicians should be aware of this potential risk in initiating a GLP-1 receptor agonist and carefully monitor exposed patients.
dc.language.isoENen_US
dc.title.enGLP-1 Receptor Agonists and the Risk of Thyroid Cancer
dc.typeArticle de revueen_US
dc.identifier.doi10.2337/dc22-1148en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed36356111en_US
bordeaux.journalDiabetes Careen_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamAHEAD_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03900050
hal.version1
hal.date.transferred2022-12-15T09:58:02Z
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Diabetes%20Care&rft.date=2022-11-10&rft.eissn=1935-5548%20(Electronic)%200149-5992%20(Linking)&rft.issn=1935-5548%20(Electronic)%200149-5992%20(Linking)&rft.au=BEZIN,%20Julien&GOUVERNEUR,%20Amandine&PENICHON,%20Marine&MATHIEU,%20Clement&GARREL,%20Renaud&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée